Anúncio
Anúncio
CBIO
Crescent Biopharma, Inc. Common Stock
10.81
USDPatrocinado
-0.16
-1.41%
09 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
10.80
-0.01
-0.09%
Relatórios de Lucros CBIO
Rácio de surpresa positiva
CBIO separação 29 de 38 últimas estimativas.
76%
Próximo Relatório
Data do Próximo Relatório
09 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$5.10M
/-$2.51
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/+97.64%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/--
Crescent Biopharma, Inc. Common Stock earnings per share and revenue
On 06 de nov. de 2025, CBIO reported earnings of -1.27 USD per share (EPS) for Q3 25, beating the estimate of -2.02 USD, resulting in a 37.18% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.39% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analistas forecast an EPS of -2.51 USD, with revenue projected to reach 5.10 milhão USD, implying an aumentar of 97.64% EPS, and -- of --% in Revenue from the last quarter.
FAQ
What were Crescent Biopharma, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Crescent Biopharma, Inc. Common Stock reported EPS of -$1.27, beating estimates by 37.18%, and revenue of $0.00, 0% as expectations.
How did the market react to Crescent Biopharma, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 5.39%, changed from $12.43 before the earnings release to $13.10 the day after.
When is Crescent Biopharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for 09 de fev. de 2026.
What are the forecasts for Crescent Biopharma, Inc. Common Stock's next earnings report?
Based on 8
analistas, Crescent Biopharma, Inc. Common Stock is expected to report EPS of -$2.51 and revenue of $5.10M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio